Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Tumor necrosis factor alpha a mononuclear cytokine
• monocytes and macrophages a mononuclear cytokine
• Tumor necrosis factor alpha a mononuclear cytokine
• Interleukin-1 beta (IL- l ⁇ ), a cytokine secreted by cells such as monocyte macrophages and dendritic cells, mediates immune and inflammatory responses.
• Nuclear factor-kappa B (NF -KB) is a pro-inflammatory transcription factor. It upregulates cytokines, including TNF ⁇ and IL- l ⁇ , and thereby mediates the inflammatory response .
• nitric oxide synthase is induced by endotoxins or cytokines (e.g., TNF ⁇ ). It catalyzes the production of nitric oxide, an important pleiotropic molecule, from L-aginine and oxygen.
• TNF ⁇ , IL- l ⁇ , NF -KB, and iNOS play important roles in many key physiological and pathological processes relating to a wide range of diseases, e.g., autoimmune diseases, cancer, atherosclerosis, and diabetes. Therefore, modulating the expression or activity of TNF ⁇ , IL-I ⁇ , NF -KB, or iNOS can lead to treatment of these diseases. See, e.g., Ogata H, Hibi T.et al Curr Pharm Des. 2003; 9(14): 1107- 13; Taylor PC. et al Curr Pharm Des. 2003; 9(14): 1095-106; Fan C, et al. J. MoI. Med 1999,. 11, 577-592; and Alcaraz et al., Current Pharmaceutical Design, 2002: 8, 215.
• This invention is based on surprising discoveries that imidazole compounds significantly inhibited production of cytokines, including TNF ⁇ and interleukin (e.g., IL- l ⁇ , IL-2, or IL-6) in mice and rats. These compounds are potentially useful in treating disorders mediated by abnormal levels of cytokines, such as inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer.
• cytokines including TNF ⁇ and interleukin (e.g., IL- l ⁇ , IL-2, or IL-6).
• one aspect of this invention features imidazole compounds of Formula I:
• A is deleted, (CR R ) n in which n is 1, 2, 3, 4, or 5, or a heteroaryl selected from the group consisting of
• each of R and R independently, is H or C 1-10 alkyl, and R is H or C 1-10 alkyl, in which C 1-10 alkyl is optionally substituted by halo, C(O)R a , OR b , SR b , S(O) 2 R b , NR c R d , C(O)NR c NR d , in which each of R a and R b , independently, is H, C 1 .
• each of R c and R d independently, is H, C 1-10 alkyl, C 1-10 haloalkyl, aryl, heteroaryl, or R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
• B is a 5-6 membered heteroaryl;
• X is deleted, (CR a R b ) m in which m is 1, 2, 3, 4, or 5, SO, SO 2 , CO, COO, CONR C' , NR C' , or NR c C0NR d' , in which each of R a' , R b' , R c' , and R d , independently, is H or C 1-10 alkyl;
• each of R 1 and R 2 independently, is H, halo, NR cl C(O)R al , OR
• X can be deleted, (CR a R b ) m , CO, COO,
• alkyl refers to a straight or branched hydrocarbon, containing e.g. 1-20 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, /-propyl, n-butyl, /-butyl, and /-butyl.
• alkoxyl refers to an -O-alkyl.
• haloakyl refers to an alkyl group having one or more halogen substituents.
• Example haloalkyl groups include CF3, C2F5,
• arylalkyl refers to alkyl substituted by aryl (or heteroaryl) and "cycloalkylalkyl” (or “heterocycloalkylalkyl”) refers to alkyl substituted by cycloalkyl (or heterocycloalkyl).
• An example arylalkyl group is benzyl.
• cycloalkyl refers to a saturated, cyclic hydrocarbon moiety, such as cyclohexyl.
• heterocycloalkyl refers to a saturated, cyclic moiety having at least one ring heteroatom (e.g., N, O, or S), such as 4-tetrahydropyranyl.
• aryl refers to a hydrocarbon moiety having one or more aromatic rings. Examples of aryl moieties include phenyl (Ph), phenylene, naphthyl, naphthylene, pyrenyl, anthryl, and phenanthryl.
• haloaryl refers to an aryl group having one or more halogen substituents.
• heteroaryl refers to a moiety having one or more aromatic rings that contain at least one heteroatom (e.g., N, O, or S).
• heteroaryl moieties include furyl, furylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl, quinolyl, isoquinolyl and indolyl.
• halo or “halogen” includes fluoro, chloro, bromo, and iodo.
• alkylamino refers to an amino group substituted by an alkyl group.
• dialkylamino refers to an amino group substituted by two alkyl groups.
• Alkyl, haloalkyl, alkoxyl, arylalkyl, heteroarylalkyl, cycloalkylakyl, heterocycloalkylalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise.
• Possible substituents on cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl include, but are not limited to, C 1 -C 10 alkyl, C2-C10 alkenyl, C 2 -CiO alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, Ci-C 2O heterocycloalkenyl, Ci-Ci 0 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C 1 -C 10 alkylamino, C1-C20 dialkylamino, arylamino, diarylamino, C 1 -C 10 alkylsulfonamino, arylsulfonamino, C 1 -C 10 alkylimino, arylimino, C 1 -C 10 alkylsul
• alkyl, alkenyl, or alkynyl include all of the above -recited substituents except C 1 -C 10 alkyl.
• Cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl can also be fused with each other.
• Another aspect of this invention relates to a method of decreasing a level of a cytokine (e.g., TNF ⁇ or interlukine) by contacting the cytokine (e.g., TNF ⁇ or interlukine) with an effective amount of one or more of the imidazole compounds of Formula I.
• the interlukine include but is not limited to IL-I ⁇ , IL-2, and IL-6.
• Still another aspect of this invention relates to a method of treating a disorder mediated by an overproduction of a cytokine (e.g., TNF ⁇ or interlukine), such as, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, diabetes mellitus, systemic lupus erythematosus, polymyositis/dermatomyositis, psoriasis, acute myelogenous leukemia, AIDS dementia complex, hematosepsis, septic shock, graft-versus-host disease, uveitis, asthma, acute pancreatitis, allergy, atherosclerosis, multiple sclerosis, or periodontal disease.
• the method includes administering to a subject in need of the treatment an effective amount of one or more of the imidazole compounds of Formula I.
• the compounds of Formula I as described above include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable.
• a salt for example, can be formed between an anion and a positively charged group (e.g., ammonium) on a compound of Formula I.
• Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumurate, glutamate, glucuronate, lactate, glutarate, and maleate.
• a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a compound of Formula I.
• Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
• the compounds also include those salts containing quaternary nitrogen atoms.
• prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds of Formula I.
• a solvate refers to a complex formed between an active compound of Formula I and a pharmaceutically acceptable solvent.
• this invention features a chemical process for preparing the aforementioned compounds (including their salts and solvates) and/or their intermediates.
• the process includes coupling a compound of the following formula:
• B is a 5-6 membered heteroaryl
• each of R 1 and R 2 independently, is H, halo, NR cl C(O)R al , OR bl , NR cl R dl , NR cl C(O)OR bl , NR cl S(O) 2 R bl , C 1-10 alkyl, or C 1 .
• each of R al and R bl independently, is H, C 1-10 alkyl, C 1-10 haloalkyl, aryl, or heteroaryl
• each of R cl and R dl independently, is H, C 1-10 alkyl, C 1-10 haloalkyl, aryl, heteroaryl, or R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group
• R 3a -X 1 -C(O)-L in which L is a leaving group (e.g., chloro, or OC(O)R), X 1 is deleted or (CR a' R b' ) m , in which m is 1, 2, 3, 4, or 5, and each of R a and R , independently, is H or C 1- 10 alkyl, and R 3a is H, halo, OC(O)R a2 , C(O)OR b2 , C(O)NR c2 R d2 , C 1-10 alkyl, C 1-10 haloalkyl, aryl, haloaryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, in which C 1-10 alkyl, C 1-10 haloalkyl, aryl, haloaryl, cycloalkyl
• the process includes coupling a compound of the following formula:
• L-X 2 -R 3b in which L is a leaving group, X 2 is deleted, SO, SO 2 , or CO, and R 3b is NR c2 R d2 , C 1 . io alkyl,
• the process includes coupling a compound of the following formula: 1 in which L is a leaving group, A' is a heteroaryl selected from the group consisting of in which each of R and R , independently, is H or C 1-10 alkyl, and R is H or C 1-10 alkyl, in which C 1-10 alkyl is optionally substituted by halo, C(O)R a , OR b , SR b , S(O) 2 R b , NR c R d , C(0)NR c NR d , in which each of R a and R b , independently, is H, C 1-10 alkyl,
• each of R c and R d independently, is H, C 1-10 alkyl, C 1-10 haloalkyl, aryl, heteroaryl, or R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group, B, R 1 , and R 2 are defined as above; with a compound of the following formula:
• R 3c is OC(O)R a2 , OR b2 , SR b2 , SO 2 R b2 , NR c2 R d2 , NR c2 C(O)R a2 , NR c2 C(O)C(O)OR a2 , NR c2 S(O) 2 R b2 , C 1-10 alkyl, C 1-10 haloalkyl, aryl, haloaryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, in which C 1-10 alkyl, C 1-10 haloalkyl, aryl, haloaryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkylalkyl or heterocycloal
• the process can also include forming a pharmaceutically acceptable salt or solvate of the compound of Formula I obtained.
• Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.
• compositions containing one or more of the imidazole compounds of Formula I for use in treating any above-described disorder, as well as this use and use of one or more of the imidazole compounds the for the manufacture of a medicament for the just-mentioned treatment.
• Examples 1-106 below provide detailed descriptions of how compounds 1- 106 were actually prepared.
• the compounds described above have one or more non-aromatic double bonds, and one or more asymmetric centers. They can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans- or E- or Z- double isomeric forms.
• Compounds of the invention also include tautomeric forms, such as keto-enol tautomers.
• Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
• One aspect of this invention is a method of lowering the level of a cytokine (e.g., TNF ⁇ or IL-I ⁇ ), e.g., by inhibiting the production of the cytokine in a subject.
• a subject refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
• the method includes administering to the subject with an effective amount of one or more of the compounds described above.
• an effective amount is the amount of the compound which is required to confer the desired effect. Effective amounts may vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co-usage with other agents.
• a cytokine in a subject can be used to treat a disorder caused by over-production of the cytokine.
• a method of treating a disorder related to cytokine over-production i.e., an inflammatory disease, an autoimmune disease, cancer, diabetes, allergy or atherosclerosis.
• An autoimmune disease includes but is not limited to rheumatoid arthritis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), multiple sclerosis, psoriasis, or septic shock.
• the method includes administering to a subject in need of the treatment an effective amount of one of the compounds described above.
• treating refers to the application or administration of a composition including the compound to a subject, who has one of the above- mentioned disorders, a symptom of the disorder, or a predisposition toward the disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptoms of the disorder, or the predisposition toward the disorder.
• one or more of the compounds described above are mixed with a pharmaceutically acceptable carrier and then administered orally, rectally, parenterally, by inhalation spray, or via an implanted reservoir.
• parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
• a composition for oral administration can be any orally acceptable dosage form including, but not limited to, tablets, capsules, emulsions and aqueous suspensions, dispersions and solutions.
• Commonly used carriers for tablets include lactose and corn starch.
• Lubricating agents, such as magnesium stearate, are also typically added to tablets.
• useful diluents include lactose and dried corn starch.
• a sterile injectable composition e.g., aqueous or oleaginous suspension
• a sterile injectable composition can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
• the sterile injectable preparation can also be a sterile injectable solution or suspension in a non- toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol.
• suitable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides).
• Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
• These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents .
• An inhalation composition can be prepared according to techniques well- known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
• One or more active compounds can be administered rectally.
• a suppository which comprises the active compounds with a suppository base.
• Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
• a gelatin rectal capsule which comprise the active compounds and a base.
• Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
• a composition that is applied to the skin can be formulated in form of oil, cream, lotion, ointment and the like.
• suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C 12).
• the preferred carriers are those in which the active ingredient is soluble.
• Emulsif ⁇ ers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
• transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers can be found in U.S. Patents 3,989,816 and 4,444,762.
• Creams are preferably formulated from a mixture of mineral oil, self- emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
• An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
• Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
• a vegetable oil such as almond oil
• An example of such an ointment is one which includes about 30% almond and about 70% white soft paraffin by weight.
• a carrier in a pharmaceutical composition must be "acceptable” in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated.
• solubilizing agents such as cyclodextrins (which form specific, more soluble complexes with the active compounds), can be utilized as pharmaceutical excipients for delivery of the active compounds.
• examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
• a suitable in vitro assay can be used to preliminarily evaluate the efficacy of any of the above-described compounds in decreasing the level of a cytokine (e.g., TNF ⁇ or IL-I ⁇ ).
• Compounds that demonstrate high activity in the preliminary screening can further be screened by in vivo assays (Example 107 below).
• a test compound is administered to an animal (e.g., a mouse model) and its effects in lowering the level of a cytokine are then assessed.
• the compounds can further be examined to verify their efficacy in treating a disorder mediated by cytokine overproduction.
• a compound can be administered to an animal (e.g., a mouse model) having inflammatory bowl disease and its therapeutic effects are then assessed. Based on the results, appropriate dosage ranges and administration routes can also be determined.
• Example 7 Compound 7: (3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)-l,2,4-oxadiazol-5- yl)-N,N-dimethylmethanamine was prepared in a manner similar to that described in Example 4.
• Example 12 Compound 12 2-(3-(5-(methoxymethyl)-l,2,4-oxadiazol-3- yl)phenyl)imidazo[l,2-b]pyridazine was prepared in a manner similar to that described in Example 4.
• Example 18 Compound 18: 2-(3-(5-(fluoromethyl)-l,2,4-oxadiazol-3- yl)phenyl)imidazo[l,2-b]pyridazine was prepared in a manner similar to that described in Example 1.
• Example 19 Compound 19: 2-(3-(5-ethyl-l,2,4-oxadiazol-3-yl)phenyl)imidazo[l,2- b]pyridazine was prepared in a manner similar to that described in Example 1.
• 5-carboxamide was prepared in a manner similar to that described in Example 1.
• Example 31 Compound 31 : 2-(3-(5-(fluoromethyl)-l,2,4-oxadiazol-3-yl)-5-(2- methoxyethoxy)phenyl)imidazo[l,2-b]pyridazine was prepared in a manner similar to that described in Example 28.
• Example 35 Compound 35: 3-(3-(imidazo[l,2-b]pyridazin-2-yl)-5-(2- methoxyethoxy)phenyl)-l,2,4-oxadiazole-5-carboxylic acid was prepared in a manner similar to that described in Example 28.
• Example 38 Compound 38: 3-(3-(imidazo[l,2-b]pyridazin-2-yl)-5-(2- methoxyethoxy)phenyl)-N-(2,2,2-trifluoroethyl)-l,2,4-oxadiazole-5-carboxamide was prepared in a manner similar to that described in Example 28.
• Example 42 Compound 42: N-(3-(imidazo[l,2-b]pyridazin-2-yl)-5-(2- methoxyethoxy)benzyl)-4-chlorobenzamide was prepared in a manner similar to that described in Example 28.
• Example 47 Compound 47: N-(3-(imidazo[l,2-b]pyridazin-2-yl)-5-(2- methoxyethoxy)benzyl)-3-chlorobenzenesulfonamide was prepared in a manner similar to that described in Example 28.
• Example 50 N-(2-(diethylamino)ethyl)-2-(3-(3-(imidazo[l,2-b]pyridazin-
• Example 52 Compound 52: 2-(3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)-l,2,4- oxadiazol-5-yl)-N-(((S)-tetrahydrofuran-2-yl)methyl)acetamide was prepared in a manner similar to that described in Example 1.
• Example 57 Compound 57: 3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)-N-(2- morpholinoethyl)-l,2,4-oxadiazole-5-carboxamide was prepared in a manner similar to that described in Example 1.
• Example 59 N-cyclopentyl-3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)- l,2,4-oxadiazole-5-carboxamide was prepared in a manner similar to that described in Example 1.
• Example 62 Compound 62: N-(2-(dimethylamino)ethyl)-3-(3-(imidazo[l ,2-b]pyridazin-2- yl)phenyl)-l,2,4-oxadiazole-5-carboxamide was prepared in a manner similar to that described in Example 1.
• Example 63 Compound 63: (4-ethylpiperazin-l-yl)(3-(3-(imidazo[l,2-b]pyridazin-2- yl)phenyl)-l,2,4-oxadiazol-5-yl)methanone was prepared in a manner similar to that described in Example 1.
• Example 66 Compound 66: 3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)-N,N-dimethyl- l,2,4-oxadiazole-5-carboxamide was prepared in a manner similar to that described in
• Example 1 1H NMR (DMSO-d 6 , 400 MHz): ⁇ 9.034(s, IH), 8.757(s, IH), 8.549(s, IH),
• Example 68 Compound 68: 3-(3-(imidazo[l,2-b]pyridazin-2-yl)phenyl)-N-methyl- 1,2,4- oxadiazole-5-carboxamide was prepared in a manner similar to that described in
• Example 69 Compound 69 : 2-(3 -(imidazo [ 1 ,2-b]pyridazin-2-yl)phenylamino)nicotinamide was prepared as outlined and described below.
• Example 73 N-cyclopropyl-2-(3-(imidazo[l,2-b]pyridazin-2- yl)phenylamino)nicotinamide was prepared in a manner similar to that described in Example 69.
• Example 79 Compound 79: N-(3-(imidazo[l,2-b]pyridazin-2-yl)-5-(5-(piperazin-l- ylmethyl)-l,2,4-oxadiazol-3-yl)phenyl)methanesulfonamide was prepared in a manner similar to that described in Example 75.
• Example 81 Compound 81 : 2-(3-(5-(morpholinomethyl)-l,2,4-oxadiazol-3- yl)phenyl)imidazo[l,2-b]pyridazine was prepared in a manner similar to that described in Example 4.
• Example 83 Compound 83 : Nl -((3-(3-(imidazo[ 1 ,2-b]pyridazin-2-yl)phenyl)- 1 ,2,4- oxadiazol-5-yl)methyl)-N2,N2-dimethylethane-l,2-diamine was prepared in a manner similar to that described in Example 4.
• Example 84 Compound 84: 2-(3-(5-(morpholinomethyl)-l,2,4-oxadiazol-3- yl)phenyl)imidazo[l,2-b]pyridazine was prepared in a manner similar to that described in Example 4.
• Example 88 Compound 88: N-((3-(3-(imidazo[l,2-b]pyridazin-2-yl)-phenyl)- 1,2,4- oxadiazol-5-yl)methyl)cyclopentanecarboxamide was prepared in a manner similar to that described in Example 4.
• Example 91 Compound 91 : N-((3-(3-(imidazo[ 1 ,2-b]pyridazin-2-yl)phenyl)- 1 ,2,4- oxadiazol-5-yl)methyl)isobutyramide was prepared in a manner similar to that described in Example 4.
• Example 92 Compound 92: 3-((3-(imidazo[l,2-b]pyridazin-2- yl)benzylamino)methyl)benzonitrile was prepared in a manner similar to that described in Example 2.
• Example 93 Compound 93: N-(3-(imidazo[l,2-b]pyridazin-2-yl)benzyl)-4- chlorobenzamide was prepared in a manner similar to that described in Example 2.
• Example 97 Compound 97: 3-bromo-N-((3-(2-methylimidazo[2,l-b]thiazol-6- yl)phenyl)methyl)benzamide was prepared in a manner similar to that described in Example 2.
• mice female, body weight 18 g-20 g
• Test compound suspension in 0.25% Tween 80 and 1% carboxymethylcellulose (CMC) was administered orally or parenterally, the negative control group being adminitered with the vehicle alone and the positive control group being administered with Prednisone
• mice (10 mg/kg). Half an hour later, all mice were injected intraperitoneally with lipopolysaccharide (LPS) (15 mg/kg, 10 mL/kg). Two hours after LPS injection, mice were bled for serum. Concentrations of TNF- ⁇ and IL-I ⁇ in the serum, stored at -20 0 C overnight, were determined by ELISA. Tested compounds from this invention demonstrated significant inhibition of TNF ⁇ and IL-I ⁇ production at a dose ranging from l to 1000 mg/kg.
• LPS lipopolysaccharide

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Transplantation (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pulmonology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40588767

Family Applications (1)

Country Status (11)

Cited By (30)

Families Citing this family (8)

Citations (4)

Family Cites Families (40)

• 2007
  • 2007-11-02 US US11/934,154 patent/US7868001B2/en not_active Expired - Fee Related
• 2008
  • 2008-07-04 TW TW097125251A patent/TWI419692B/zh not_active IP Right Cessation
  • 2008-10-31 JP JP2010532289A patent/JP5733982B2/ja not_active Expired - Fee Related
  • 2008-10-31 CA CA2704431A patent/CA2704431A1/en not_active Abandoned
  • 2008-10-31 MY MYPI20101943 patent/MY153065A/en unknown
  • 2008-10-31 RU RU2010122333/04A patent/RU2485113C2/ru not_active IP Right Cessation
  • 2008-10-31 WO PCT/US2008/082027 patent/WO2009059162A1/en not_active Ceased
  • 2008-10-31 KR KR1020107011579A patent/KR20100101581A/ko not_active Abandoned
  • 2008-10-31 EP EP08843535.9A patent/EP2214669B1/en not_active Not-in-force
  • 2008-10-31 MX MX2010004774A patent/MX2010004774A/es active IP Right Grant
  • 2008-10-31 AU AU2008318491A patent/AU2008318491B2/en not_active Ceased

Patent Citations (4)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events